KAIROS PHARMA, LTD. Operating Expenses
KAIROS PHARMA, LTD. (KAPA) reported Operating Expenses of $1.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- KAIROS PHARMA, LTD. operating expenses for the quarter ending 2026-06-30 was $1.42M, a 2.68% decline year-over-year.
- KAIROS PHARMA, LTD. operating expenses for the quarter ending 2026-03-31 was $1.69M, a 33.49% increase year-over-year.
- KAIROS PHARMA, LTD. operating expenses for the quarter ending 2025-12-31 was $1.42M, a 2.14% decline year-over-year.
- KAIROS PHARMA, LTD. operating expenses for the quarter ending 2025-09-30 was $1.44M, a 274.67% increase year-over-year.
- KAIROS PHARMA, LTD. operating expenses for fiscal 2025 was $5.57M, a 137.81% increase from fiscal 2024.
- KAIROS PHARMA, LTD. operating expenses for fiscal 2024 was $2.34M, a 36.70% increase from fiscal 2023.
- KAIROS PHARMA, LTD. operating expenses for fiscal 2023 was $1.71M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.42M 10-Q · filed 2026-08-12 | $3.11M 10-Q · filed 2026-08-12 | $4.52M derived: sum of 3 quarters · filed 2026-08-12 | $5.96M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.69M 10-Q · filed 2026-05-13 | $3.10M derived: sum of 2 quarters · filed 2026-05-13 | $4.54M derived: sum of 3 quarters · filed 2026-05-13 | $6.00M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.85M derived: sum of 2 quarters · filed 2026-03-31 | $4.31M derived: sum of 3 quarters · filed 2026-08-12 | $5.57M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.44M 10-Q · filed 2025-11-14 | $2.89M derived: sum of 2 quarters · filed 2026-08-12 | $4.16M 10-Q · filed 2025-11-14 | $5.60M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.46M 10-Q · filed 2026-08-12 | $2.72M 10-Q · filed 2026-08-12 | $4.17M derived: sum of 3 quarters · filed 2026-08-12 | $4.55M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.27M 10-Q · filed 2026-05-13 | $2.71M derived: sum of 2 quarters · filed 2026-05-13 | $3.10M derived: sum of 3 quarters · filed 2026-05-13 | $3.32M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.83M derived: sum of 2 quarters · filed 2026-03-31 | $2.05M derived: sum of 3 quarters · filed 2026-03-31 | $2.34M 10-K · filed 2026-03-31 |
| 2024-09-30 | $383.00K 10-Q · filed 2025-11-14 | $605.00K derived: sum of 2 quarters · filed 2025-11-14 | $897.00K 10-Q · filed 2025-11-14 | $1.98M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $222.00K 10-Q · filed 2025-08-12 | $514.00K 10-Q · filed 2025-08-12 | $1.60M derived: sum of 3 quarters · filed 2025-08-12 | $1.89M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $287.00K 10-Q · filed 2025-05-14 | $1.38M derived: sum of 2 quarters · filed 2025-05-14 | $1.66M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $1.38M derived: sum of 2 quarters · filed 2025-04-15 | $1.71M 10-K · filed 2025-04-15 | |
| 2023-09-30 | $287.00K 10-Q · filed 2024-11-14 | $625.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |